[<sup>68</sup>Ga]‑DOTA‑conjugated somatostatin receptor‑targeting peptide PET for the differentiation between meningioma and glioblastoma: A case report and review of the literature
Laurèl Rauschenbach(University of Bonn), Philipp Dammann(Essen University Hospital), Sied Kebir(University of Bonn), Cornelius Deuschl(Essen University Hospital), Ulrich Sure(University of Duisburg-Essen), Christoph Berliner(Klinik und Poliklinik für Nuklearmedizin), Celia Dobersalske(Düsseldorf University Hospital), Ken Herrmann(Essen University Hospital), Felix Gerach(Essen University Hospital), Tobias Blau(University of Duisburg-Essen)
Cited by 1
Related Papers
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
|The Lancet Oncology|2007|808
Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction
|Journal of Clinical Oncology|2006|464
Radiotheranostics: a roadmap for future development
|The Lancet Oncology|2020|306
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
|European Journal of Cancer|2023|156
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
|Clinical Cancer Research|2022|145